Vif have been one of the most studied targets for HIV therapeutic strategies . Many antiVif inhibitors including complementary peptides, have been proposed . However, most of the maximal affinities reported for antiVif inhibitors have been > 100 nM. On the other hand, the newly defined interfaces of Vif-human protein asymmetric hetero-dimers 9 remain unexplored for inhibitors.